Company: HCWB
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0000950170-25-046724
Chunk: 21

Company: HCW Biologics Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1
Chunk 21
---
 in non-human primates before the end of 2025.  Results of these studies are expected to show the optimal construction for lead product candidates.    

18 

Example of Class I TRBC Molecule

Second-Generation Multi-Functional Immune Cell Stimulator

    HCW 11-002

HCW11-002 is a Class I TRBC molecule that contains the same immune moieties as HCW9218, and it has demonstrated its promising capabilities in stimulating immune cells in preclinical studies. Based on this potential, the Company is considering accelerating the development of HCW11-002 for senescence-associated indications.  

Senescence-Associated Diseases

The Class I TRBC Molecules have potential for the treatment of senescence-associated indications, such as bronchopulmonary dysplasia (“BPD”), chronic deep wrinkles and senile lentigo (age spots) removal.  BPD is a form of chronic lung disease that causes long-term breathing problems in premature babies. The condition often results in poor growth and development. An estimated 10,000 to 15,000 babies in the United States develop BPD each year.  There is no known cure for BPD, which involves high morality and morbidities. 

Aesthetics treatments represent a large and growing market due to the aging population. For example, the global botulinum toxin market was valued at $6.4 billion (USD) in 2022 and growing at a CAGR of 11.50% from 2022 to 2030. The market is expected to reach $15.2 billion (USD) by 2030. (See:  Global Growth Report, Fortune Business Insights.) 

Class III TRBC Molecules:  Immune Cell Engagers

Class III TRBC Molecules are second-generation immune-cell engagers capable of targeting tissue factor and other cell-surface antigens associated with diseased cells.  Class III TRBC Molecules are part of a new class of therapeutic treatments based on the development of immune-cell engagers. Among these are T-cell targeted molecules  — antibodies engineered to redirect T cells to recognize and kill cancer cells — that are being developed to treat cancer and tackle issues that could potentially lead to treatment that is more effective and safer for cancer patients.  

Recent deal activity indicates that the pharmaceutical industry and the biotech industry have recognized the benefits of Enhanced Immune Cell Engagers, in particular T-Cell Engagers.  Recent notable deals in the immune cell eng